Sharekhan's research report on Ipca Laboratories
Resolution of the USFDA issues could provide a further upside. Strong outlook for 2-3 years, led by growth across key business verticals such as domestic formulations, APIs and institutional anti-malarial drugs. Despite USFDA issues being unresolved, the company is on a strong footing. We expect sales and profit to clock a CAGR of 20% and 28%, respectively over FY2019-FY2021.
Outlook
We re-initiate coverage on Ipca with a Buy recommendation and a price target of Rs 1,135, valuing stock at 20x FY2021E earnings.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
Read More
